Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

Inflammatory hindfoot arthrodesis outcomes compared

Choice of arthrodesis for patients with rheumatoid arthritis or spondyloarthritis hindfoot disease should be guided by the extent of damage present, research indicates.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

GE Healthcare introduces KUBio factory

GE Healthcare, the healthcare business of GE, today introduced KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

4 Sep 2012

Infliximab may offer new hope for people with difficult-to-treat depression

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry.

4 Sep 2012

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including rheumatoid arthritis (RA), today announced results from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

For people suffering from rheumatoid arthritis, pain is the crucial factor in their personal perception of the condition. The doctors treating them, however, assess the severity of the disease based on the swelling of the joints. This discrepancy often leads to conflict between patients and their physicians, as a study by Daniel Aletaha and Paul Studenic from the University Department of Internal Medicine III at the MedUni Vienna has now revealed in more detail for the first time.

23 Aug 2012

FDA extends action date for Pfizer’s tofacitinib NDA review

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).

22 Aug 2012

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

22 Aug 2012

GM-CSF depletion suppresses pain in people with arthritis-related conditions

The research relates to a family of molecules firstly discovered in Melbourne that applied to blood cell development. One of these, granulocyte macrophage colony-stimulating factor or GM-CSF, acts as a messenger between cells acting at a site of inflammation.

22 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

The American Pain Society (APS) announced today it is accepting applications for research grants from the newly established Sharon S. Keller Chronic Pain Research Program.

16 Aug 2012

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Absence of Puma and Bim protein leads to autoimmune diseases

Inflammatory hindfoot arthrodesis outcomes compared

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

GE Healthcare introduces KUBio factory

Infliximab may offer new hope for people with difficult-to-treat depression

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

FDA extends action date for Pfizer’s tofacitinib NDA review

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

GM-CSF depletion suppresses pain in people with arthritis-related conditions

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

New attack on arthritis pain

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in